Clopidogrel or apixaban in atrial fibrillation patients unsuitable for vitamin-K antagonists for stroke prevention in atrial fibrillation? Lessons from the recent aspirin-controlled trials

被引：0
|
作者：
Verheugt, F. W. A. [1 ]
Jaspersfocks, J. [2 ]
Brouwer, M. A. [2 ]
机构：
[1] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Cardiol, NL-6525 ED Nijmegen, Netherlands
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2011年 / 183卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：672 / 672
页数：1
相关论文
共 50 条
  • [21] Patients' knowledge and perspectives on vitamin K antagonists for stroke prevention in atrial fibrillation: implications for treatment quality
    Polovina, Marija
    Djikic, Dijana
    Vlajkovic, Ana
    Vilotijevic, Matej
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (03): : 239 - 240
  • [22] Vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) in very elderly naive patients
    Granziera, S.
    Bertozzo, G.
    Marigo, L.
    Petruzzellis, F.
    Rossi, K.
    Infante, T.
    Pletti, S.
    Nante, G.
    Manzato, E.
    Pengo, V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 559 - 559
  • [23] Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation
    Hanna, Michael S.
    Mohan, Puneet
    Knabb, Robert
    Gupta, Elora
    Frost, Charles
    Lawrence, John H.
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALISTS FOR THE PRIX GALIEN USA AWARDS 2013, 2014, 1329 : 93 - 106
  • [24] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Athanasakis, Kostas
    Boubouchairopoulou, Nadia
    Karampli, Eleftheria
    Tarantilis, Filippos
    Savvari, Paraskevi
    Bilitou, Aikaterini
    Kyriopoulos, John
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 123 - 133
  • [25] The procoagulant effect of Vitamin-K antagonists in patients with atrial fibrillation, atherosclerosis and deep venous thrombosis
    Al Dieri, R.
    ten Cate-Hoek, A. J.
    ten Cate, H.
    Hemker, H. C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 857 - 857
  • [26] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [27] EFFICACY AND SAFETY OF APIXABAN COMPARED WITH WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN PATIENTS TAKING CONCOMITANT ASPIRIN
    Alexander, John H.
    Lopes, Renato
    McMurray, John
    Atar, Dan
    Wojdyla, Daniel
    Aylward, Philip
    Husted, Steen
    Alings, Marco
    Huber, Kurt
    Hanna, Michael
    Pais, Prem
    Lewis, Basil
    Goto, Shinya
    Pouleur, Hubert
    Steg, Philippe
    Verheugt, Freek
    Granger, Christopher
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1697 - E1697
  • [28] A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE
    Hess, Connie N.
    Al-Khatib, Sana M.
    Granger, Christopher B.
    Lopes, Renato
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2013, 11 (09) : 1105 - 1114
  • [29] Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
    Kostas Athanasakis
    Nadia Boubouchairopoulou
    Eleftheria Karampli
    Filippos Tarantilis
    Paraskevi Savvari
    Aikaterini Bilitou
    John Kyriopoulos
    American Journal of Cardiovascular Drugs, 2017, 17 : 123 - 133
  • [30] Stroke Prevention Versus Bleeding Risk of Vitamin-K Antagonists: A Double-Edged Sword in Patients with Atrial Fibrillation Who Require Surgery
    Dobrev, Dobromir
    Goette, Andreas
    Ravens, Ursula
    CARDIOVASCULAR THERAPEUTICS, 2009, 27 (04) : 223 - 225
12345